<DOC>
	<DOC>NCT00868530</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of on-demand treatment with Xyntha in Chinese hemophilia A subjects.</brief_summary>
	<brief_title>Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects equal or more than 6 years of age with mild, moderate or severe hemophilia A (FVIII activity: more than 5%, 15%, or less than 1%, respectively) Subjects with previous exposure to FVIII replacement therapy If human immunodeficiency virus (HIV) positive, documented cluster of differentiation (CD4) count more than 200/µL within 6 months of study entry Diagnosed with any bleeding disorder in addition to hemophilia A Current FVIII inhibitor or history of FVIII inhibitor (defined as positive result of the reporting laboratory) Subject has no history of exposure to FVIII products (previously untreated patient [PUP]) Subject is currently utilizing primary FVIII prophylaxis Subjects anticipating elective surgery that may be planned to occur in the 6 months following study entry Treated with immunomodulatory therapy within 30 days prior to study entry or planned use for the duration of their study participation Participated in another investigational drug or device study within 30 days prior to study entry or planned participation for the duration of their study participation Subjects with a known hypersensitivity to hamster protein Significant hepatic or renal impairment (alanine aminotransferase [ALT] and aspartate aminotransferase [AST] &gt;5 x upper limit of normal [ULN], bilirubin &gt;2 mg/dL or serum creatinine &gt;1.25 x ULN) Prothrombin Time &gt;1.5 x ULN Platelet count &lt;80,000 / µL Pregnant or breastfeeding women Unwilling or unable to follow the terms of the protocol Any condition which may compromise the subject's ability to comply with and/or perform studyrelated activities or that poses a clinical contraindication to study participation, in the opinion of the Investigator or Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>On-demand treatment; Hemostatic Efficacy Assessments; Factor VIII recovery; Factor VIII Inhibitor; Chinese</keyword>
</DOC>